Oddo Securities Analysts Give MediGene AG (ETR:MDG1) a €12.00 Price Target
MediGene AG (ETR:MDG1) has been assigned a €12.00 ($14.12) price target by Oddo Securities in a report released on Tuesday. The brokerage presently has a “buy” rating on the stock.
Several other research firms have also recently weighed in on MDG1. Baader Bank set a €19.00 ($22.35) price objective on MediGene AG and gave the stock a “buy” rating in a report on Thursday, August 3rd. Independent Research GmbH set a €12.00 ($14.12) price objective on MediGene AG and gave the stock a “neutral” rating in a report on Monday, May 29th.
MediGene AG (MDG1) traded down 2.051% during midday trading on Tuesday, hitting €9.981. The stock had a trading volume of 3,333 shares. The firm’s 50-day moving average price is €10.89 and its 200 day moving average price is €11.70. The company’s market cap is €201.10 million. MediGene AG has a 12 month low of €6.63 and a 12 month high of €15.19.
About MediGene AG
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors.
Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.